NOVEL RECOMBINANT STRAIN OF MYCOBACTERIUM SMEGMATIS AND USE OF SAME
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 23, 2024
app pub date -
Mar 21, 2022
filing date -
Mar 22, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A recombinant Mycobacterium strain co-expressing MIF and IL-7, and a composition containing the strain as an active ingredient are disclosed. The strain and the composition are suitable for preventing or treating cancer. The strain induces a maximized anticancer immune response by stably expressing MIF and IL-7 through a mycobacteria-derived replicable plasmid, such as a pMyong2 shuttle vector. Accordingly, the strain and the composition may be usefully used as an efficient anticancer live vaccine composition that induces multiple cellular and humoral immune responses through single administration of the recombinant strain.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully